Sharon Curtis
Child & Adolescent Psychiatry · Dyer, INNPI 1679796403
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $81,888 of the $101,953 with a category attached, or 80.3%. Supernus Pharmaceuticals, Inc. accounts for 91.8% of it on its own, with 26 other manufacturers making up the rest. Among child & adolescent psychiatry clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 432 payments — averaging $236.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Supernus Pharmaceuticals, Inc.$94K
- Neuronetics, Inc.$1K
- AbbVie$1K
- Teva Pharmaceuticals USA, Inc.$733
- Otsuka America Pharmaceutical, Inc.$727
- Johnson & Johnson$564
- plus $4K from 21 others
What the payments were for
- Speaking & faculty fees$81,88880%
- Travel & lodging$8,6558%
- Food & beverage$11,33111%
- Education$790%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Supernus Pharmaceuticals, Inc. | 207 | $93,590 |
| Neuronetics, Inc. | 2 | $1,389 |
| AbbVie(2 entities) | 36 | $1,080 |
| Teva Pharmaceuticals USA, Inc. | 14 | $733 |
| Otsuka America Pharmaceutical, Inc. | 20 | $727 |
| Johnson & Johnson | 12 | $564 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 9 | $544 |
| Tris Pharma Inc | 15 | $487 |
| Corium, LLC | 30 | $469 |
| Alkermes, Inc. | 10 | $419 |
| Neurocrine Biosciences, Inc. | 9 | $380 |
| Lundbeck LLC | 18 | $294 |
| Ironshore Pharmaceuticals Inc. | 7 | $222 |
| E.r. Squibb & Sons, L.L.C. | 4 | $206 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $161 |
| Sunovion Pharmaceuticals Inc. | 12 | $153 |
| Axsome Therapeutics, Inc. | 1 | $120 |
| Idorsia Pharmaceuticals US Inc | 1 | $104 |
| Almatica Pharma LLC | 5 | $95 |
| Bausch Health US, LLC | 2 | $38 |
| Noven Therapeutics, LLC | 2 | $36 |
| Shire North American Group Inc | 2 | $36 |
| Collegium Pharmaceutical, Inc. | 1 | $30 |
| Neos Therapeutics, LP | 2 | $30 |
| Indivior Inc. | 1 | $19 |
| Alfasigma USA, Inc. | 1 | $14 |
| Rhodes Pharmaceuticals L.p. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- QELBREE$90,343
- NEUROSTAR TMS THERAPY SYSTEM$1,389
- ARISTADA$931
- LYBALVI$480
- VRAYLAR$437
- CAPLYTA$317
- REXULTI$250
- INVEGA SUSTENNA$243
- ARISTADA INITIO$233
- UZEDY$219
- Auvelity$120
- COBENFY$119
- ABILIFY MAINTENA$116
- ABILIFY ASIMTUFII$116
- INGREZZA$105
- QUVIVIQ$104
How this compares
$101,953 in reported general payments places this provider in the 95th percentile of 56 child & adolescent psychiatry providers in Indiana.
See all child & adolescent psychiatry providers in Indiana →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 12 | $86,100 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 12 | $2,281 |
| Vilazodone Hcl | 13 | $505 |
| Divalproex Sodium | 12 | $485 |
| Quetiapine Fumarate | 13 | $335 |
| Modafinil | 11 | $173 |
| Buspirone Hcl | 12 | $86 |
| Bupropion Hcl SrBupropion Hcl | 13 | $78 |
| Topiramate | 13 | $77 |
| Fluoxetine Hcl | 13 | $61 |
| Alprazolam | 12 | $24 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo | $733 | $86,10012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 56 child & adolescent psychiatry providers in Indiana.
Other child & adolescent psychiatry in Dyer
- Cyrus SolhkhahDyer$36
- Christopher McDougleIndianapolis$17K
- Ann KledzikIndianapolis$12K
- Teresita Briones RamiloIndianapolis$7K
- Mitchell GoldsteinSouth Bend$6K
- Lia KettenisBloomington$6K
- Hugh StarksIndianapolis$4K
- Daniel KinseyGoshen$3K
- Michael WellingIndianapolis$3K
- Sanjay MishraCarmel$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.